Seer, Inc.

NASDAQ•SEER

執行長: Dr. Omid C. Farokhzad M.D., Ph.D.

板塊: Healthcare

行業: Biotechnology

上市日期: 2020-12-04

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

聯絡資訊

3800 Bridge Parkway, Suite 102, Redwood City, CA, 94065, United States

650-453-0000

seer.bio

市值

$110.58M

本益比 (TTM)

-1.5

股息率

52周最高

$2.41

52周最低

$1.65

52周範圍

41%

排名54Top 78.1%

2.7

F-Score

改良版 Piotroski 分析

基於 7 年期基本面

疲弱 • 2.7 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2019-2025

財務儀表板

Q4 2025 數據

營業收入

$4.20M+0.00%

近4季度走勢

每股收益

-$0.29+0.00%

近4季度走勢

自由現金流

-$11.10M+0.00%

近4季度走勢

2025 Annual 財報亮點

核心亮點

Total Revenue Increased 17% Total revenue reached $16.6M in 2025, up 17% ($2.4M increase), driven by higher product sales and service revenue.

Gross Profit and Loss Improvement Gross profit grew 20% to $8.5M; Net loss improved 15% to $(73.6M), reflecting reduced operating expenses.

Operating Expenses Significantly Reduced Total operating expenses decreased 19% to $86.5M, primarily due to 25% reduction in SG&A expenses ($14.0M decrease).

Proteograph ONE Throughput Gains Third-generation Proteograph ONE assay launched in May 2025, delivering 3.6x throughput increase over previous assay versions.

關注風險

Continued Operating Losses Expected Company has incurred significant losses since 2017; expects to continue incurring net losses and negative cash flows near term.

Market Acceptance Uncertainty Commercial success hinges on broad scientific and market acceptance of Proteograph, which may take longer than anticipated.

Intellectual Property Enforcement Risk Reliance on patents; challenges or failure to enforce IP rights could allow competitors to commercialize similar products.

Reliance on Key Customers Related party revenue was 5% of total revenue in 2025; loss of key customers could materially impact financial results.

未來展望

Drive Installed Base Utilization Focus on driving higher utilization and consumable pull-through from the rapidly expanding installed base across all customer types.

Expand Population-Scale Cohorts Announced several population-scale studies in 2025; actively discussing expansion with additional key biobanks globally.

Leadership in AI Biology Platform Pursue strategic ecosystem partnerships to establish leadership as preferred proteomic data platform for AI-driven discovery.

New Product Innovation Focus Aim to continuously innovate and develop new products, applications, and analysis tools across the R&D value chain.

同行對比

營業收入 (TTM)

GLUE

$123.67M

+63.5%

NRIX

$71.78M

+27.2%

KYMR

$39.20M

-16.7%

毛利率 (最新季度)

KYMR

2763.6%

-2680.7pp

FHTX

91.3%

-245.3pp

CCCC

83.6%

+13.4pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
KYMR	$7.27B	-24.1	-29.1%	4.7%
PHVS	$1.91B	-8.3	-70.8%	0.3%
NRIX	$1.47B	-6.3	-64.2%	9.2%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

-0.0%

基本持平

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年5月11日

每股收益:-

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料